Sanofi completes acquisition of Blueprint Medicines

赛诺菲完成对Blueprint Medicines的收购

Paris, July 18, 2025

巴黎，2025年7月18日

. Sanofi today announces the completion of its

赛诺菲今天宣布已完成其

acquisition of Blueprint Medicines Corporation

收购蓝图医药公司

(Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases.

（Blueprint），为其产品组合增加了一种已商业化的药物、一条有前景的管线，以及一家专注于系统性肥大细胞增多症（SM）这种罕见免疫疾病和其他KIT驱动疾病的公司的专业知识。

In addition, the acquisition of Blueprint brings Sanofi an established presence among allergists, dermatologists, and immunologists which is expected to enhance Sanofi’s ability to advance its growing immunology pipeline.

此外，收购Blueprint使赛诺菲在过敏科、皮肤科和免疫科领域获得了既定的地位，这有望增强赛诺菲推进其不断增长的免疫学产品线的能力。

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and EU. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs..

此次收购包括一种罕见的免疫疾病药物Ayvakit/Ayvakyt（avapritinib），该药已在美国和欧盟获批。Ayvakit/Ayvakyt是唯一被批准用于治疗晚期和惰性系统性肥大细胞增多症（ASM和ISM）的药物，这种疾病的特点是骨髓、皮肤、胃肠道及其他器官中异常肥大细胞的积累和激活。

The acquisition also includes elenestinib, a next-generation medicine for SM that is a potent and highly selective KIT D816V inhibitor with limited central nervous system penetration. The oral investigational ISM medication is the subject of HARBOR, a phase 2/3 study (clinical study identifier: NCT04910685).

此次收购还包括 elenestinib，这是一种用于治疗 SM 的下一代药物，是一种强效且高度选择性的 KIT D816V 抑制剂，中枢神经系统渗透有限。这款口服 ISM 在研药物是 HARBOR 项目的研究对象，该项目是一项 2/3 期研究（临床研究标识符：NCT04910685）。

The ongoing, randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of elenestinib plus symptom-directed therapy in patients with ISM and smoldering SM..

持续进行的随机、双盲、安慰剂对照研究旨在评估依莱诺替尼联合症状导向治疗在ISM和隐匿性SM患者中的疗效和安全性。

Sanofi also acquired BLU-808, an investigational oral, highly potent and selective wild-type KIT inhibitor. Wild-type KIT plays a central role in mast cell activation, which is implicated in a broad range of inflammatory diseases.

赛诺菲还收购了BLU-808，一种研究中的口服、高效且选择性强的野生型KIT抑制剂。野生型KIT在肥大细胞活化中起核心作用，而肥大细胞活化与多种炎症性疾病有关。

The tender offer for all outstanding shares of Blueprint common stock, par value $0.001 per share expired at 17:00 EDST, on Thursday, July 17, 2025. The minimum tender condition and all of the other conditions to the offer have been satisfied, and on July 17, 2025, Sanofi accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn..

针对Blueprint全部已发行普通股（每股面值0.001美元）的要约收购于2025年7月17日星期四东部夏令时间17:00到期。最低要约条件及所有其他要约条件均已达成，并于2025年7月17日，赛诺菲接受了所有有效提交且未被有效撤回的股份支付，并将迅速完成付款。

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Blueprint through the merger of a wholly owned subsidiary of Sanofi with and into Blueprint, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Blueprint continuing as the surviving corporation, and becoming an indirect, wholly owned subsidiary of Sanofi.

在接受要约股份后，赛诺菲通过其全资子公司与Blueprint的合并完成了对Blueprint的收购，该合并是根据《特拉华州普通公司法》第251(h)条进行的，合并后Blueprint作为存续公司继续存在，并成为赛诺菲的间接全资子公司。

Sanofi is financing the transaction with a combination of cash on hand and proceeds from commercial paper issuances and the acquisition will not have a significant impact on Sanofi’s financial guidance for 2025. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026.

赛诺菲将通过手中的现金，结合商业票据发行收益为本次交易提供资金，本次收购不会对赛诺菲2025年的财务指导产生重大影响。该交易将立即提高毛利率，并在2026年后提升营业利润和每股收益。

.

。

In connection with the merger, all Blueprint shares not validly tendered in the tender offer have been converted into the right to receive $129.00 per share in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, plus one non-transferable contractual contingent right per share, representing the right to receive contingent payments of up to an aggregate amount of $6.00 per share in cash, without interest, upon the achievement of specified milestones on or prior to the expiration of the applicable milestone period.

与合并相关，所有在要约收购中未有效投标的Blueprint股份已被转换为每股获得129.00美元现金的权利，不计利息，并受适用法律规定所需的任何税款扣缴，以及每股一项不可转让的合同或有权利，代表在达到指定里程碑或在适用的里程碑期限到期之前，获得最高总计每股6.00美元的或有付款权利，不计利息。

.

。

As of July 18, 2025, Blueprint common stock will cease to be traded on the NASDAQ Global Select Stock Market.

截至2025年7月18日，Blueprint普通股将停止在纳斯达克全球精选股票市场交易。

About Ayvakit

关于Ayvakit

Ayvakit (avapritinib) is the first and only medicine approved by the US Food and Drug Administration (FDA) to treat the root cause of SM. It was FDA approved for the treatment of advanced SM in June 2021 and indolent SM in May 2023. It now is indicated in adults with ISM, adults with advanced SM, including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL), and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Ayvakit（阿伐普利尼）是美国食品药品监督管理局（FDA）批准的首个也是唯一一个用于治疗SM根本原因的药物。它于2021年6月获得FDA批准用于治疗晚期SM，并于2023年5月获批用于惰性SM。该药物目前适用于患有ISM的成人、患有晚期SM的成人，包括侵袭性SM（ASM）、伴有相关血液肿瘤的SM（SM-AHN）和肥大细胞白血病（MCL），以及携带PDGFRA外显子18突变的不可切除或转移性胃肠道间质瘤（GIST）成人患者，包括PDGFRA D842V突变。

The medicine is approved in the EU as Ayvakyt for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation.

该药物在欧盟被批准作为Ayvakyt，用于治疗症状性治疗无法充分控制的中度至重度症状的成人ISM患者、至少接受过一种系统治疗的成人ASM、SM-AHN或MCL患者，以及携带PDGFRA D842V突变的不可切除或转移性GIST成人患者。

Globally, the medicine is approved for one or more indications in 16 countries, including China where it is marketed by CStone Pharmaceuticals, paying tiered percentage royalties on sales. .

全球范围内，该药物已在包括中国在内的16个国家获得批准用于一种或多种适应症，其在中国由基石药业销售，并按销售额支付分层百分比的特许权使用费。

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

赛诺菲是一家以研发为驱动、以人工智能为助力的生物制药公司，致力于改善人们的生活并实现引人注目的增长。我们凭借对免疫系统的深刻理解，发明能够治疗和保护全球数百万人的药物和疫苗，并通过创新的研发管线造福更多人群。我们的团队秉承一个使命：追逐科学的奇迹以改善人们的生活；这激励我们推动进步，为我们服务的员工和社区带来积极影响，同时应对当今最紧迫的医疗、环境和社会挑战。

.

。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

赛诺菲在欧盟欧洲证券交易所上市，股票代码为SAN，在纳斯达克上市，股票代码为SNY。

Media Relations

媒体关系

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

| +33 6 25 09 14 25 |

sandrine.guendoul@sanofi.com

桑德琳·格恩杜尔@赛诺菲.com

Evan Berland

埃文·贝兰德

| +1 215 432 0234 |

| +1 215 432 0234 |

evan.berland@sanofi.com

evan.berland@赛诺菲.com

Léo Le Bourhis

里奥·勒布尔希斯

| +33 6 75 06 43 81 |

| +33 6 75 06 43 81 |

leo.lebourhis@sanofi.com

leo.lebourhis@sanofi.com

Victor Rouault

维克多·鲁奥

| +33 6 70 93 71 40 |

| +33 6 70 93 71 40 |

victor.rouault@sanofi.com

victor.rouault@sanofi.com

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

| +1 516 521 2929 |

timothy.gilbert@sanofi.com

timothy.gilbert@sanofi.com

Léa Ubaldi

莉娅·乌巴尔迪

| +33 6 30 19 66 46 |

| +33 6 30 19 66 46 |

lea.ubaldi@sanofi.com

lea.ubaldi@sanofi.com

Investor Relations

投资者关系

Thomas Kudsk Larsen

托马斯·库兹克·拉森

| +44 7545 513 693 |

| +44 7545 513 693 |

thomas.larsen@sanofi.com

托马斯.拉森@赛诺菲.com

Alizé Kaisserian

阿丽泽·凯塞里安

| +33 6 47 04 12 11 |

| +33 6 47 04 12 11 |

alize.kaisserian@sanofi.com

alize.kaisserian@sanofi.com

Felix Lauscher

费利克斯·劳舍尔

| +1 908 612 7239 |

| +1 908 612 7239 |

felix.lauscher@sanofi.com

felix.lauscher@sanofi.com

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

| +1 781 249 1766 |

keita.browne@sanofi.com

keita.browne@sanofi.com

Nathalie Pham

纳塔莉·范

| +33 7 85 93 30 17 |

| +33 7 85 93 30 17 |

nathalie.pham@sanofi.com

纳塔莉·法姆@赛诺菲.com

Tarik Elgoutni

塔里克·埃尔戈特尼

| +1 617 710 3587 |

| +1 617 710 3587 |

tarik.elgoutni@sanofi.com

塔里克·埃尔戈蒂尼@赛诺菲.com

Thibaud Châtelet

蒂博·沙泰莱

| +33 6 80 80 89 90 |

| +33 6 80 80 89 90 |

thibaud.chatelet@sanofi.com

thibaud.chatelet@sanofi.com

Yun Li

李云

| +33 6 84 00 90 72 |

| +33 6 84 00 90 72 |

yun.li3@sanofi.com

yun.li3@sanofi.com

Sanofi forward-looking statements

赛诺菲前瞻性声明

Forward-looking statements are statements that are not historical facts. These statements may include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product, and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.

前瞻性声明是指并非历史事实的声明。这些声明可能包括关于产品市场和其他潜力的预测和估计，或关于产品未来潜在收入及其基本假设的声明，关于未来财务结果、事件、运营、服务、产品开发和潜力的计划、目标、意图和期望的声明，以及关于未来表现的声明。

Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “will be”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements.

前瞻性陈述通常可以通过“预期”、“预计”、“相信”、“将是”、“意图”、“估计”、“计划”等词语及类似表述加以识别。尽管赛诺菲的管理层认为这些前瞻性陈述中反映的预期是合理的，但投资者应注意，前瞻性信息和陈述受到各种风险和不确定性的影响，其中许多难以预测且通常超出赛诺菲的控制范围，可能导致实际结果和发展与这些前瞻性信息和陈述所表达或暗示的内容存在重大差异。

These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful and other risks associated with executing business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, risks related to future opportunities and plans for the combi.

这些风险和不确定性包括但不限于：意外的监管行动或延迟，或一般性的政府监管，可能影响产品的可用性或商业潜力；产品可能无法取得商业成功；与执行业务合并交易相关的其他风险，例如业务可能无法成功整合、整合可能比预期更困难、耗时或成本更高，或收购的预期收益无法实现；以及与未来机会和联合计划相关的风险。

Attachment

附件

Press Release

新闻稿

Share

分享